Plans afoot to grow complex 3D human tumour microenvironment in the lab
A project is in the pipeline to grow a complex 3D tumour microenvironment in vitro.
A project has been awarded 2.43 million euros for the development of the first complex three-dimensional human 'tumour microenvironment' in the laboratory.
The funding was provided by the European Research Council to Queen Mary, University of London, in an effort to revolutionise the field of cancer cell research through bioengineering methods.
It is hoped that the creation of such tumour microenvironments will replace inadequate techniques where human cancer cells are grown in isolation on plastic surfaces.
Dubbed the CANBUILD project, it might also pave the way for better testing of new drugs that target the human tumour microenvironment.
The multi-disciplinary team involved in the study will make the most of the latest advances in tissue engineering, biomechanics, imaging and stem cell biology in the hopes of engineering a 3D human tumour in which the different cell types of the microenvironment will communicate, evolve and grow in vitro.
"Growing an in vitro model which contains all these types of cells will allow us to watch how the cells communicate and how the tumour grows, teaching us more about what is going on in this complex system and hopefully giving us a model we can test new drugs on," said Professor Fran Balkwill.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...